The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
申请公布号
WO2017019726(A1)
申请公布日期
2017.02.02
申请号
WO2016US44167
申请日期
2016.07.27
申请人
MERCK SHARP & DOHME CORP.;CONVERSO, Antonella;KAUFMAN, Mildred Lee;RODZINAK, Kevin, J.
发明人
CONVERSO, Antonella;KAUFMAN, Mildred Lee;RODZINAK, Kevin, J.